Drugs / Tunlametinib
Trials 20
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04683354 | Dec 2020 → Sep 2022 | cancer | Kechow Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03990077 | May 2020 → Jul 2021 | non-small cell lung carcinoma | Shanghai Kechow Pharma, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03976050 | Jun 2019 → Nov 2020 | cancer | Shanghai Kechow Pharma, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03781219 | Jul 2018 → Dec 2023 | neoplasm | Shanghai Kechow Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03973151 | Sep 2017 → Jan 2021 | melanoma | Shanghai Kechow Pharma, Inc. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07170293 | Aug → Sep 2027 expected | solid adenocarcinoma with mucin production | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07507526 | Apr 2026 → Apr 2028 expected | gastric adenocarcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07463677 | Mar 2026 → May 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07446270 | Mar 2026 → Oct 2027 expected | colorectal cancer | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06970353 | May 2025 → Dec 2026 expected | thyroid cancer, nonmedullary, 3 | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05900219 | Sep 2023 → Sep 2025 | non-small cell lung carcinoma | Shanghai Kechow Pharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05233332 | Feb 2022 → Jan 2024 | — | Shanghai Kechow Pharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05331105 | Oct 2021 → Oct 2025 overdue | neurofibromatosis type 1, plexiform neurofibroma | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05263453 | Sep 2021 → Sep 2024 | melanoma | Shanghai Kechow Pharma, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05217303 | Nov 2020 → Feb 2023 | melanoma | Shanghai Kechow Pharma, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06008106 | Nov 2023 → Sep 2027 expected | melanoma | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06008119 | Oct 2023 → Dec 2026 expected | colorectal cancer | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07445022 | Jan 2026 → Sep 2028 expected | melanoma | Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT07302841 | Jan 2026 → Jun 2027 expected | pancreatic neoplasm | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06985316 | May 2025 → Apr 2028 expected | colorectal cancer | Liu Huang | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07714447 Background | Nov 2026 → Feb 2029 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tunlametinib | “Tunlametinib: 9 mg per dose, administered orally twice daily (BID).” NCT07714447 ↗11“Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor” PMID 38867257 ↗ Jun 2024 |
| Known as | HL-085 | “observing and evaluating the efficacy and safety of Tunlametinib (HL-085) in the treatment of refractory solid tumors” NCT07170293 ↗10“Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor” PMID 38867257 ↗ Jun 2024 |
| Action | Inhibit | “Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor” PMID 38867257 ↗ Jun 2024 |
| Modality | Small molecule | — CHEMBL5095241 ↗ |
| Route | Oral | “orally administered” PMID 36600247 ↗ Jan 2023 |